 SEATTLE, Feb. 10, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS, a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical needs in oncology and infectious diseases, with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders: 